Management of patients with advanced non-small cell lung cancer: role of gefitinib

Vamsidhar Velcheti1, Daniel Morgensztern2,3,4, Ramaswamy Govindan3,41Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Division of Hematology-Oncology, St. Louis Veterans Hospital, St. Louis, MO, USA; 3Division of Medical Oncology, Washington University School of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vamsidhar Velcheti, Daniel Morgensztern, Ramaswamy Govindan
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/55703b790ac14771a4f891fff26a39f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55703b790ac14771a4f891fff26a39f0
record_format	dspace
spelling	oai:doaj.org-article:55703b790ac14771a4f891fff26a39f02021-12-02T00:12:55ZManagement of patients with advanced non-small cell lung cancer: role of gefitinib1177-54751177-5491https://doaj.org/article/55703b790ac14771a4f891fff26a39f02010-04-01T00:00:00Zhttp://www.dovepress.com/management-of-patients-with-advanced-non-small-cell-lung-cancer-role-o-a4265https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Vamsidhar Velcheti1, Daniel Morgensztern2,3,4, Ramaswamy Govindan3,41Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Division of Hematology-Oncology, St. Louis Veterans Hospital, St. Louis, MO, USA; 3Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA; 4Alvin J Siteman Cancer Center, St. Louis, MO, USAAbstract: Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to improve survival in a placebo-control study, however, led to its withdrawal in the United States though it is available in many other countries Subsequent studies nevertheless showed comparable efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved progression-free survival compared to chemotherapy in patients with activating mutations in the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the results of these large randomized studies and discuss the role of gefitinib in the treatment of advanced NSCLC.Keywords: gefitinib, non-small cell lung cancer Vamsidhar VelchetiDaniel MorgenszternRamaswamy GovindanDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 83-90 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Vamsidhar Velcheti Daniel Morgensztern Ramaswamy Govindan Management of patients with advanced non-small cell lung cancer: role of gefitinib
description	Vamsidhar Velcheti1, Daniel Morgensztern2,3,4, Ramaswamy Govindan3,41Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Division of Hematology-Oncology, St. Louis Veterans Hospital, St. Louis, MO, USA; 3Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA; 4Alvin J Siteman Cancer Center, St. Louis, MO, USAAbstract: Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to improve survival in a placebo-control study, however, led to its withdrawal in the United States though it is available in many other countries Subsequent studies nevertheless showed comparable efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved progression-free survival compared to chemotherapy in patients with activating mutations in the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the results of these large randomized studies and discuss the role of gefitinib in the treatment of advanced NSCLC.Keywords: gefitinib, non-small cell lung cancer
format	article
author	Vamsidhar Velcheti Daniel Morgensztern Ramaswamy Govindan
author_facet	Vamsidhar Velcheti Daniel Morgensztern Ramaswamy Govindan
author_sort	Vamsidhar Velcheti
title	Management of patients with advanced non-small cell lung cancer: role of gefitinib
title_short	Management of patients with advanced non-small cell lung cancer: role of gefitinib
title_full	Management of patients with advanced non-small cell lung cancer: role of gefitinib
title_fullStr	Management of patients with advanced non-small cell lung cancer: role of gefitinib
title_full_unstemmed	Management of patients with advanced non-small cell lung cancer: role of gefitinib
title_sort	management of patients with advanced non-small cell lung cancer: role of gefitinib
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/55703b790ac14771a4f891fff26a39f0
work_keys_str_mv	AT vamsidharvelcheti managementofpatientswithadvancednonsmallcelllungcancerroleofgefitinib AT danielmorgensztern managementofpatientswithadvancednonsmallcelllungcancerroleofgefitinib AT ramaswamygovindan managementofpatientswithadvancednonsmallcelllungcancerroleofgefitinib
_version_	1718403866290028544

Management of patients with advanced non-small cell lung cancer: role of gefitinib

Ejemplares similares